{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:58:50Z","timestamp":1790895530032,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"crossref","award":["U01FD005272"],"award-info":[{"award-number":["U01FD005272"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.eplepsyres.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T02:01:23Z","timestamp":1497405683000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)"],"prefix":"10.1016","volume":"135","author":[{"given":"Md. Motiur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Alatawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annya V.","family":"Plotkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy L.","family":"Peissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eplepsyres.2017.06.007_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1525-1497.2003.20130.x","article-title":"Adverse drug event monitoring at the Food and Drug Administration","volume":"18","author":"Ahmad","year":"2003","journal-title":"J. Gen. Intern. Med."},{"issue":"11","key":"10.1016\/j.eplepsyres.2017.06.007_bib0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","article-title":"Perspectives on the use of data mining in pharmaco-vigilance","volume":"28","author":"Almenoff","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0015","series-title":"Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy, November 2006","author":"American Academy of Neurology","year":"2017"},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0020","unstructured":"Approved drug products with therapeutic equivalence evaluations (Orange Book), 33rd ed. 2013. https:\/\/books.google.com\/books?id=5uSMDAAAQBAJ&pg=PR10&lpg=PR10&dq=there+is+no+more+than+a+5%25+chance+that+a+generic+product+that+is+not+truly+equivalent+to+the+reference+will+be+approved&source=bl&ots=5W68qzSFqV&sig=KEUyQJ5eWbrqCh1xNZJCN18FsNY&hl=en&sa=X&ved=0ahUKEwjaro3zt4rQAhXCYSYKHej9DHsQ6AEIIDAB#v=onepage&q=there%20is%20no%20more%20than%20a%205%25%20chance%20that%20a%20generic%20product%20that%20is%20not%20truly%20equivalent%20to%20the%20reference%20will%20be%20approved&f=false. (Accessed 16 March 2017)."},{"issue":"6","key":"10.1016\/j.eplepsyres.2017.06.007_bib0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMoa0909801","article-title":"Suicide-related events in patients treated with antiepileptic drugs","volume":"363","author":"Arana","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.eplepsyres.2017.06.007_bib0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1528-1157.2000.tb00166.x","article-title":"The cost of epilepsy in the United States: an estimate from population-based clinical and survey data","volume":"41","author":"Begley","year":"2000","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2017.06.007_bib0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.yebeh.2008.06.001","article-title":"Generic substitution in the treatment of epilepsy: patient and physician perceptions","volume":"13","author":"Berg","year":"2008","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.eplepsyres.2017.06.007_bib0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.eplepsyres.2017.06.007_bib0045","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000262876.37269.8b","article-title":"What\u2019s the problem with generic antiepileptic drugs?: a call to action","volume":"68","author":"Berg","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.eplepsyres.2017.06.007_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200023030-00001","article-title":"Is generic prescribing acceptable in epilepsy?","volume":"23","author":"Besag","year":"2000","journal-title":"Drug Saf."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0055","unstructured":"CDC | Epilepsy. http:\/\/www.cdc.gov\/epilepsy\/basics\/fast-facts.htm. (Accessed 10 March 2017)."},{"issue":"2","key":"10.1016\/j.eplepsyres.2017.06.007_bib0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1871523016666161109144021","article-title":"Hypersensitivity reactions from excipients in systemic glucocorticoid formulations","volume":"15","author":"Calogiuri","year":"2016","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"issue":"4","key":"10.1016\/j.eplepsyres.2017.06.007_bib0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11910-016-0640-y","article-title":"Practice update: review of anticonvulsant therapy","volume":"16","author":"Chong","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.eplepsyres.2017.06.007_bib0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2005.12.010","article-title":"Are there potential problems with generic substitution of antiepileptic drugs?","volume":"15","author":"Crawford","year":"2006","journal-title":"Seizure \u2212 Eur. J. Epilepsy"},{"issue":"2","key":"10.1016\/j.eplepsyres.2017.06.007_bib0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/0976-500X.130086","article-title":"Skin rash during treatment with generic itraconazole","volume":"5","author":"De Vuono","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0080","unstructured":"Drugs@FDA Glossary of Terms. http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm079436.htm#ANDA. (Accessed 16 March 2017)."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0085","unstructured":"Drugs@FDA: FDA Approved Drug Products. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. (Accessed 8 May 2017)."},{"issue":"13","key":"10.1016\/j.eplepsyres.2017.06.007_bib0090","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMc0904562","article-title":"Hypersensitivity to generic drugs with soybean oil","volume":"361","author":"Duenas-Laita","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.eplepsyres.2017.06.007_bib0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance: three Dutch examples","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.eplepsyres.2017.06.007_bib0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S1092852900008452","article-title":"The goal of epilepsy therapy: no seizures, no side effects, as soon as possible","volume":"9","author":"Engel","year":"2004","journal-title":"CNS Spectr."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0105","unstructured":"FAERS. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm. (Accessed 16 March 2017)."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0110","unstructured":"FDA | List of authorized generic drugs. http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/approvalapplications\/abbreviatednewdrugapplicationandagenerics\/ucm126389.htm. (Accessed 16 March 2017)."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0115","unstructured":"FDA | NTI definition. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology\/UCM263465.pdf. (Accessed 16 March 2017)."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0120","unstructured":"FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm100197.htm. (Accessed 9 May 2017)."},{"issue":"3","key":"10.1016\/j.eplepsyres.2017.06.007_bib0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ana.24470","article-title":"Confusing placebo effect with natural history in epilepsy: a big data approach","volume":"78","author":"Goldenholz","year":"2015","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2017.06.007_bib0130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pds.4160","article-title":"Antiepileptic drugs and risk of suicide attempts: a case-control study exploring the impact of underlying medical conditions","volume":"26","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.eplepsyres.2017.06.007_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0317167100051957","article-title":"Generic substitution for brand name antiepileptic drugs: a survey","volume":"27","author":"Guberman","year":"2000","journal-title":"Can. J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.eplepsyres.2017.06.007_bib0140","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(07)70105-9","article-title":"Antiepileptic drugs: generic versus branded treatments","volume":"6","author":"Heaney","year":"2007","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2017.06.007_bib0145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/009885881203800403","article-title":"Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs","volume":"38","author":"Hottinger","year":"2012","journal-title":"Am. J. Law Med."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0150","series-title":"Presented as a Poster in the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management","article-title":"Identification of generic drugs in the FDA adverse event reporting system","author":"Iyer","year":"2016"},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/PSY.0b013e3182738826","article-title":"The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects","volume":"75","author":"Kate Faasse","year":"2013","journal-title":"Psychosom. Med."},{"issue":"16","key":"10.1016\/j.eplepsyres.2017.06.007_bib0160","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1212\/01.wnl.0000259400.30539.cc","article-title":"Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy","volume":"68","author":"Liow","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2017.06.007_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2012.10.010","article-title":"Generic antiepileptic drug prescribing: a cross-sectional study","volume":"26","author":"Meyer","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"11","key":"10.1016\/j.eplepsyres.2017.06.007_bib0170","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/archneurol.2009.232","article-title":"THe value of specifying brand-name antiepileptic drugs","volume":"66","author":"Ng","year":"2009","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2017.06.007_bib0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2017.06.007_bib0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1535-7511.2008.00261.x","article-title":"Generic antiepileptic drugs: current controversies and future directions","volume":"8","author":"Privitera","year":"2008","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0185","unstructured":"Reports Received and Reports Entered into FAERS by Year. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm070434.htm. (Accessed 16 March 2017)."},{"issue":"7","key":"10.1016\/j.eplepsyres.2017.06.007_bib0190","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2017.06.007_bib0195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/pds.3928","article-title":"Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR)","volume":"25","author":"Schuerch","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.eplepsyres.2017.06.007_bib0200","first-page":"81","article-title":"The controversy over generic antiepileptic drugs","volume":"15","author":"Shaw","year":"2010","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","article-title":"Epilepsy treatment in adults and adolescents: expert opinion, 2016","volume":"69","author":"Shih","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.eplepsyres.2017.06.007_bib0210","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1377\/hlthaff.2010.0431","article-title":"The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money","volume":"30","author":"Shrank","year":"2011","journal-title":"Health Aff. (Millwood)"},{"issue":"9","key":"10.1016\/j.eplepsyres.2017.06.007_bib0215","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.mayocp.2012.05.019","article-title":"Antiepileptic drugs 2012: recent advances and trends","volume":"87","author":"Sirven","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0220","unstructured":"Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4372b1-01-FDA.pdf. (Accessed 9 May 2017)."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0225","unstructured":"Teva. Lamotrigine. http:\/\/ir.tevapharm.com\/phoenix.zhtml?c=73925&p=irol-newsArticle_Print&ID=1557132. (Accessed 8 May 2017)."},{"issue":"9","key":"10.1016\/j.eplepsyres.2017.06.007_bib0230","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13095","article-title":"Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard","volume":"56","author":"Ting","year":"2015","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2017.06.007_bib0235","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5698\/1535-7511-16.3.209","article-title":"AES position statement on generic substitution of antiepileptic drugs","volume":"16","author":"Vossler","year":"2016","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2017.06.007_bib0240","unstructured":"WHO | Epilepsy. http:\/\/www.who.int\/mediacentre\/factsheets\/fs999\/en\/. (Accessed 10 March 2017)."},{"issue":"7","key":"10.1016\/j.eplepsyres.2017.06.007_bib0245","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.3390\/ph3072090","article-title":"Difficulties in treatment and management of epilepsy and challenges in new drug development","volume":"3","author":"Wahab","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"10.1016\/j.eplepsyres.2017.06.007_bib0250","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1528-1167.2009.02159.x","article-title":"Economic impact of epilepsy in the United States","volume":"50","author":"Yoon","year":"2009","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117301560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117301560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:36:40Z","timestamp":1760276200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121117301560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":50,"alternative-id":["S0920121117301560"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.06.007","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}